Nasdaq
$69.55▲ 1.47%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $13.62BShares out 200M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
20- 10.13Pre-market26.10.13 19:018-KKey event#●●●#●●●#●●●
BridgeBio Pharma, Inc.Bullish
BridgeBio Pharma announced that the FDA has accepted its New Drug Application (NDA) for oral infigratinib for the treatment of children with achondroplasia under Priority Review. The FDA has set a PDUFA target action date of February 4, 2027, and the company is prepared to launch the product in the U.S. upon approval.…more
$69.55+1.47%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.21After-hours26.09.22 07:214Ownership
BridgeBio Pharma, Inc.
BridgeBio Pharma insider Neil Kumar filed a Form 4 on September 21, 2026, reporting changes in beneficial ownership of company securities that occurred on September 17, 2026. This filing provides transparency regarding the insider's equity position in the company.…more
$69.55+1.47%vs prev closeView filingShare - 8.31Regular26.09.01 04:548-KKey event
BridgeBio Pharma, Inc.
BridgeBio Pharma entered into a voluntary agreement with the U.S. government on August 31, 2026, to expand access to its medicines and lower costs for patients. Under this agreement, the company will expand Medicaid access to its marketed medicine, Attruby, via the GENEROUS Model and expects to be exempt from future government pricing mandates.…more
$69.55+1.47%vs prev closeView filingShare
19 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 3d agoPre-market26.10.22 20:30#●●●#●●●
BridgeBio to Report Q3 2026 Financial Results on October 29
BridgeBio Pharma will release its third-quarter 2026 financial results and business updates after the market close on October 29, 2026. A conference call will be held on the same day to discuss the company's performance and program updates.…more
$69.55+1.47%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.16Pre-market26.10.16 20:30
●●●●●●●● ●●●●● ●●●●●●
BridgeBio Pharma has granted restricted stock units totaling 57,853 shares to 32 new employees as an inducement for their hiring. This equity grant is a standard corporate practice conducted in accordance with Nasdaq listing rules.…more
$69.55+1.47%vs prev close - 10.12Overnight26.10.12 15:56
●●●●●●●● ●●●●● ●●●●●●
BridgeBio's acoramidis demonstrated an 18% lower risk of composite clinical outcomes compared to tafamidis in a real-world study of 2,684 ATTR-CM patients. The findings highlight significant reductions in cardiovascular hospitalizations, supporting its potential as a preferred treatment option.…more
$69.55+1.47%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report